Washington, D.C. 20549





Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934


Date of Report (Date of earliest event reported): October 12, 2020



(Exact name of registrant as specified in its charter)

Delaware   001-15070   52-1253406

(State or other jurisdiction

of incorporation)

  (Commission File Number)   (IRS Employer Identification No.)



15245 Shady Grove Road, Suite 470

Rockville, MD




(Address of principal executive offices)   (Zip Code)


Registrant’s telephone number, including area code: (301) 208-9191


Not Applicable

(Former name or former address, if changed since last report.)


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


¨   Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨   Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨   Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨   Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class Trading Symbol(s) Name of each exchange on which registered


Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging Growth Company ¨ 


If an emerging growth company, indicate by check mark if registrant has elected not to use the extended transition period for complying with any new or revised accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨







Item 8.01 Other Events


On October 12, 2020, RegeneRx Biopharmaceuticals, Inc. (the “Company”) issued a press release announcing that it has verbally agreed to a short-term financing transaction with one of its major stockholders, and members of its board of directors and management. The funding will provide working capital through the first quarter of 2021 and while we await the completion of our phase 3 dry eye clinical trial (ARISE-3) expected later this year. A copy of the press release is attached as Exhibit 99.1 hereto and incorporated by reference herein.



Item 9.01 Financial Statements and Exhibits.


(d) Exhibits.


Exhibit No.   Description
99.1   Press Release dated October 12, 2020









Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.



  By:   /s/ J.J. Finkelstein    
    J.J. Finkelstein   
    President and Chief Executive Officer   




Date: October 12, 2020




RegeneRX Biopharmaceutic... (QB) (USOTC:RGRX)
Historical Stock Chart
From Nov 2020 to Dec 2020 Click Here for more RegeneRX Biopharmaceutic... (QB) Charts.
RegeneRX Biopharmaceutic... (QB) (USOTC:RGRX)
Historical Stock Chart
From Dec 2019 to Dec 2020 Click Here for more RegeneRX Biopharmaceutic... (QB) Charts.